Back to mobile site

Jefferies Reiterates Buy Rating on Acrivon Therapeutics Inc (ACRV)

March 2, 2026 3:39 PM EST Send to a Friend
Jefferies analyst Roger Song reiterated a Buy rating and $14.00 price target on Acrivon Therapeutics Inc (NASDAQ: ACRV)The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login